Wren Laboratories NETest 2.0

Wren Laboratories, a Branford, Connecticut-based liquid biopsy diagnostics provider, has launched NETest 2.0 for neuroendocrine tumor (NET) diagnostics. NETest 2.0 uses an artificial intelligence-enhanced, noninvasive 51-gene mRNA expression algorithm to help diagnose NETs from 1 mL of blood collected in a proprietary tube. According to the company, the assay has greater than 95 percent sensitivity for detecting NETs, greater than 90 percent accuracy in identifying progressive disease, and predicts patient response to peptide receptor radionuclide therapy with a 98 percent positive predictive value and a 93 percent negative predictive value. The company offers the test under CLIA, CAP, and New York State Department of Heath CLEP certification. With the new launch, the company has discontinued the first generation of the assay.